Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Biotechnology

Healthcare
$162.86 -0.45%

-$0.71 today

Market cap
$16.48B
Beta
0.40
P/E (TTM)
23.8
EPS (TTM)
$6.65
52W Low $122.14High $169.57

Volume 1.60M

Average 1.18M

NBIX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Neurocrine Biosciences, Inc.NASDAQ: NBIX

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows in line with its trailing trend

Q3 FY2026 weighted avg shares of 101.6M shares rose 2.2% year over year, ahead of the +1.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.6% from the prior quarter. Over 3 fiscal years it compounded at +1.3% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2.2% holds above the trailing-twelve-month pace of +1.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
101.6M+0.6% QoQ
Last fiscal yearDec 2025
99.5M-0.9% YoY
LTMSep 2026
100.65M+1.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.2%——
1 year-0.9%——
3-year CAGR+1.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
99.5M USD
Year-over-year change
-0.9%
4-year CAGR
+1.3%

Weighted Avg Shares vs competitors

How NBIX compares with its peers on the latest reported figures

  • NBIX's LTM Sep 2026 weighted avg shares of 100.65M shares is the 4th highest of the 10 companies compared; the peer median is 62.03M shares.
  • Its year-over-year change of +1.1% is the lowest of 10, against a peer median of +4.0%.
  • Over three fiscal years its annual growth of +1.3% compares with a peer median of +2.4%.
NBIX Competitors Peer median
Weighted Avg Shares for NBIX and competitors
Company Period LTM YoY 3-year CAGR
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026171M +2.1%+1.6%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026166.7M +4.0%+2.4%
BHVNBiohaven Ltd.LTM Jun 2026131.06M +31.1%+34.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026100.65M +1.1%+1.3%
JAZZJazz Pharmaceuticals plcLTM Sep 202662.7M +3.0%-0.8%
GHRSGH Research PLCLTM Mar 202662.03M +15.9%+5.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.4%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.36M +3.1%+1.7%
AXSMAxsome Therapeutics, Inc.LTM Jun 202650.84M +4.3%+7.0%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 202641.9M +115.2%+32.7%
Peer median (excluding NBIX) 62.03M+4.0%+2.4%

Competitors are the stored peer set for NBIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.13B1.49B1.89B2.36B2.86B
Cost of Revenue14.3M23.2M39.7M34M52.1M
Gross Profit1.12B1.47B1.85B2.32B2.81B
Gross Margin98.7%98.4%97.9%98.6%98.2%
Research & Development328.1M463.8M565M731.1M1.02B
Selling, General & Admin583.3M752.7M887.6M1.01B1.16B
Operating Expenses1.02B1.22B1.6B1.75B2.19B
Depreciation & Amortization10.9M15.6M21.3M27.1M30.1M
EBITDA138.1M236.6M416.1M639.7M666.6M
EBITDA Margin12.2%15.9%22.0%27.2%23.3%
Operating Income102.5M249M250.9M570.5M619.1M
Operating Margin9.0%16.7%13.3%24.2%21.6%
Interest Income011.2M091M90.3M
Interest Expense25.8M7.1M4.6M126.6M0
Other Income / Expenses(1.1M)(35.1M)81.2M(84.5M)86.3M
Income Before Tax101.4M213.9M332.1M486M705.4M
Pre-Tax Margin8.9%14.4%17.6%20.6%24.7%
Income Tax Expense11.8M59.4M82.4M144.7M226.8M
Net Income89.6M154.5M249.7M341.3M478.6M
Net Margin7.9%10.4%13.2%14.5%16.7%
EPS (Basic)0.951.612.563.404.81
EPS (Diluted)0.921.562.473.294.67
Weighted Avg Shares94.6M95.8M97.7M100.4M99.5M
Weighted Avg Shares (Diluted)97.9M98.9M101M103.7M102.5M

Neurocrine Biosciences, Inc.

NASDAQ:NBIX

Intrinsic Alpha fair value

Locked

Current Price

$162.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.